# Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04499963** · PHASE2 · COMPLETED · sponsor: **Richard Bedlack, M.D., Ph.D.** · enrollment: 100 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Theracurmin HP

## Key facts

- **NCT ID:** NCT04499963
- **Lead sponsor:** Richard Bedlack, M.D., Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-28
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499963, "Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04499963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*